Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-013517
Filing Date
2023-02-27
Accepted
2023-02-27 21:53:13
Documents
1
Period of Report
2023-02-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 8161
  Complete submission text file 0001209191-23-013517.txt   9548
Mailing Address C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Business Address
Gupta Rishi (Reporting) CIK: 0001537370 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39247 | Film No.: 23678109

Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Issuer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations